Mereo Biopharma Group Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
39
- Stock Symbol
-
MREO
- Investments
-
2
- Share Price
-
$0.32
- (As of Thursday Closing)
Mereo Biopharma Group General Information
Description
Developer of drugs and therapies catering to patients with rare diseases and cancer. The company is engaged in the development and commercialization of innovative therapeutics that aim to improve outcomes for people in both oncology and rare diseases.
Contact Information
Website
www.mereobiopharma.comCorporate Office
- 4th Floor, 1 Cavendish Place
- London W1G 0QF
- England, United Kingdom
Corporate Office
- 4th Floor, 1 Cavendish Place
- London W1G 0QF
- England, United Kingdom
Mereo Biopharma Group Stock Performance
As of 17-Dec-2020, Mereo Biopharma Group’s stock price is $0.32. Its current market cap is $121M with 339M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.32 | $0.31 | $0.17 - $0.66 | $121M | 339M | 66.07 | -$1.54 |
Mereo Biopharma Group Financials Summary
As of 30-Sep-2026, Mereo Biopharma Group has a trailing 12-month revenue of $800K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| Revenue | 800 | 500 | 0 | 10,000 |
| EBITDA | (26,532) | (42,647) | (43,836) | (28,187) |
| Net Income | (26,938) | (41,878) | (43,253) | (29,466) |
| Total Assets | 29,583 | 45,917 | 76,390 | 66,499 |
| Total Debt | 577 | 202 | 6,429 | 5,952 |
Mereo Biopharma Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mereo Biopharma Group Comparisons
Industry
Financing
Details
Mereo Biopharma Group Competitors (14)
One of Mereo Biopharma Group’s 14 competitors is Biosceptre, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biosceptre | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom | ||||
| Redx Pharma | Venture Capital-Backed | Macclesfield, United Kingdom | ||||
| Sitryx | Venture Capital-Backed | Oxford, United Kingdom |
Mereo Biopharma Group Patents
Mereo Biopharma Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023149978-A1 | Cancer biomarkers and cancer treatments | Inactive | 04-Feb-2022 | ||
| WO-2023149977-A1 | Methods for treating cancer | Inactive | 04-Feb-2022 | ||
| AU-2019380595-A1 | Methods and monitoring of treatment with vegf/dll4 binding agent | Inactive | 15-Nov-2018 | ||
| CA-3119458-A1 | Methods and monitoring of treatment with vegf/dll4 binding agent | Pending | 15-Nov-2018 | ||
| EP-3880697-A2 | Methods and monitoring of treatment with vegf/dll4 binding agent | Inactive | 15-Nov-2018 | C07K14/515 |
Mereo Biopharma Group Signals
Mereo Biopharma Group Investments & Acquisitions (2)
Mereo Biopharma Group’s most recent deal was a Merger/Acquisition with OncoMed Pharmaceuticals for . The deal was made on 23-Apr-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| OncoMed Pharmaceuticals | 23-Apr-2019 | Merger/Acquisition | Drug Discovery | ||
| Novartis (Mid-Stage Clinical Product Portfolio) | 29-Jul-2015 | Corporate Asset Purchase | Buildings and Property |
Mereo Biopharma Group ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Mereo Biopharma Group Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Mereo BioPharma Europe | Amsterdam, Netherlands | 2025 | |
| OncoMed Pharmaceuticals | Redwood City, CA | 2004 |
Mereo Biopharma Group FAQs
-
When was Mereo Biopharma Group founded?
Mereo Biopharma Group was founded in 2015.
-
Where is Mereo Biopharma Group headquartered?
Mereo Biopharma Group is headquartered in London, United Kingdom.
-
What is the size of Mereo Biopharma Group?
Mereo Biopharma Group has 39 total employees.
-
What industry is Mereo Biopharma Group in?
Mereo Biopharma Group’s primary industry is Drug Discovery.
-
Is Mereo Biopharma Group a private or public company?
Mereo Biopharma Group is a Public company.
-
What is Mereo Biopharma Group’s stock symbol?
The ticker symbol for Mereo Biopharma Group is MREO.
-
What is the current stock price of Mereo Biopharma Group?
As of 17-Dec-2020 the stock price of Mereo Biopharma Group is $0.32.
-
What is the current market cap of Mereo Biopharma Group?
The current market capitalization of Mereo Biopharma Group is $121M.
-
What is Mereo Biopharma Group’s current revenue?
The trailing twelve month revenue for Mereo Biopharma Group is $800K.
-
Who are Mereo Biopharma Group’s competitors?
Biosceptre, Genentech, Verona Pharma, Redx Pharma, and Sitryx are some of the 14 competitors of Mereo Biopharma Group.
-
What is Mereo Biopharma Group’s annual earnings per share (EPS)?
Mereo Biopharma Group’s EPS for 12 months was -$1.54.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process